COMP <GO>
MRVI vs SEPN // RETURN ON INVESTED CAPITAL (ROIC)
Maravai LifeSciences Holdings Inc. (Class A) (NASDAQ) VS. Septerna Inc. (NASDAQ) • 15-METRIC TALLY: MRVI 0
— SEPN 7
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: SEPN
LAST: $7.19 (-7.94%) • MKT CAP: $2.03B
roic
-35.00%
LAST: $43.20 (-1.82%) • MKT CAP: $2.05B
roic
-20.70%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MRVI VS. SEPN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MRVI | SEPN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 18.30% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -35.00% | -20.70% | -14.30 | SEPN | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.22% | 5.19% | -8.41 | SEPN | /fcf-yield <GO> |
| Operating Margin | -60.00% | -60.00% | 0.00 | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | -60.00% | 0.00 | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -28.30% | 180.00% | -208.30 | SEPN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.04 | 5.87 | -2.83 | SEPN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 6/9 | -3.00 | SEPN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.2 | 62.4 | -10.20 | SEPN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.03B | $2.05B | -$25.7M | SEPN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MRVI REV | SEPN REV | MRVI GROSS % | SEPN GROSS % | MRVI FCF | SEPN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $185.7M | $46.0M | 18.3% | — | -$70.7M | $109.7M |
| FY 2024 | $259.2M | $1.1M | 41.8% | — | -$22.2M | -$69.6M |
| FY 2023 | $288.9M | $151.0K | — | — | $126.2M | -$38.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MRVI // BETA —
SEPN // BETA —